Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12116746 | 1.00 | FAAH (0.51) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12116748 | 0.92 | FAAH (0.61) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12414826 | 0.92 | FAAH (0.61) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12116743 | 0.87 | PRKCA (0.56) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12116740 | 0.87 | PRKCA (0.59) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12116739 | 0.87 | PRKCA (0.59) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL12116834 | 0.86 | FAAH (0.51) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL17467181 | 0.86 | FAAH (0.51) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL14899314 | 0.86 | LMNA (0.61) | FAAHALDH1A1MAPTCNR1HPGD | |
| SCHEMBL15483549 | 0.83 | ALDH1A1 (0.56) | FAAHALDH1A1MAPTCNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-20160024012-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-28 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LTD (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-07 | — | — | US | disclosed |
| US-8431576-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-04-30 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024012-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | FAAH 3072/4885ALDH1A1 113/4885MAPT 3460/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | FAAH 565/4885ALDH1A1 599/4885MAPT 165/4885 |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | FAAH 565/4885ALDH1A1 599/4885MAPT 165/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | FAAH 210/4885ALDH1A1 307/4885MAPT 349/4885 |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | FAAH 203/4885ALDH1A1 1082/4885MAPT 2880/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | FAAH 565/4885ALDH1A1 599/4885MAPT 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.